Amgen (AMGN) Interest Expenses (2009 - 2026)
Amgen (AMGN) posted Interest Expenses of $673.0 million for Q2 2026, up 2.44% on a QoQ basis from $657.0 million in Q1 2026, and down 3.03% year-over-year from $694.0 million in Q2 2025.
Analysis
Amgen (AMGN) Interest Expenses (2009 - 2026) Analysis & Trends
Amgen has reported Interest Expenses for 18 years, with the latest figure at $673.0 million in Q2 2026.
- On a quarterly basis, Interest Expenses fell 3.03% year-over-year to $673.0 million in Q2 2026; TTM through Jun 2026 was $2.7 billion, a 9.25% decrease from a year earlier, with the FY2025 full-year figure at $2.8 billion, down 12.68% from the prior year.
- Interest Expenses was $673.0 million for Q2 2026 at Amgen, up from $657.0 million in the prior quarter.
- The five-year high for Interest Expenses was $824.0 million in Q1 2024, with the low at $295.0 million in Q1 2022.
- Average Interest Expenses over 5 years is $640.1 million, with a median of $689.5 million recorded in 2025.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses surged 129.27% in 2023, then fell 14.11% in 2025.
- Over 5 years, Interest Expenses stood at $415.0 million in 2022, then surged by 97.83% to $821.0 million in 2023, then retreated by 9.01% to $747.0 million in 2024, then dropped by 12.58% to $653.0 million in 2025, then advanced by 3.06% to $673.0 million in 2026.
- The last three Interest Expenses figures came in at $673.0 million (Q2 2026), $657.0 million (Q1 2026), and $653.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | 20.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 673.00 Mn |
| Mar 31, 2026 | 657.00 Mn |
| Dec 31, 2025 | 653.00 Mn |
| Sep 30, 2025 | 685.00 Mn |
| Jun 30, 2025 | 694.00 Mn |
| Mar 31, 2025 | 723.00 Mn |
| Dec 31, 2024 | 747.00 Mn |
| Sep 30, 2024 | 776.00 Mn |
| Jun 30, 2024 | 808.00 Mn |
| Mar 31, 2024 | 824.00 Mn |
| Dec 31, 2023 | 821.00 Mn |
| Sep 30, 2023 | 759.00 Mn |
| Jun 30, 2023 | 752.00 Mn |
| Mar 31, 2023 | 543.00 Mn |
| Dec 31, 2022 | 415.00 Mn |
| Sep 30, 2022 | 368.00 Mn |
| Jun 30, 2022 | 328.00 Mn |
| Mar 31, 2022 | 295.00 Mn |
| Dec 31, 2021 | 335.00 Mn |
| Sep 30, 2021 | 296.00 Mn |